

Patrick H Pun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7131727/publications.pdf>

Version: 2024-02-01

47
papers

2,239
citations

430874

18
h-index

265206

42
g-index

50
all docs

50
docs citations

50
times ranked

2855
citing authors

#	ARTICLE	IF	CITATIONS
1	Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics. <i>Kidney International</i> , 2011, 79, 218-227.	5.2	217
2	Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. <i>Kidney International</i> , 2009, 76, 652-658.	5.2	187
3	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	2.2	186
4	Sudden Cardiac Death Among Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2017, 69, 684-695.	1.9	107
5	Predictors of Survival after Cardiac Arrest in Outpatient Hemodialysis Clinics. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 491-500.	4.5	103
6	Dialysate Calcium Concentration and the Risk of Sudden Cardiac Arrest in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 797-803.	4.5	95
7	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in CKD: A Meta-analysis of Patient-Level Data From 3 Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2014, 64, 32-39.	1.9	89
8	Automated External Defibrillators and Survival from Cardiac Arrest in the Outpatient Hemodialysis Clinic. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 312-320.	6.1	59
9	Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 829-835.	0.7	59
10	Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3441-3451.	6.1	52
11	Survival After Primary Prevention Implantable Cardioverter-Defibrillator Placement Among Patients With Chronic Kidney Disease. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 793-799.	4.8	45
12	The Interplay Between CKD, Sudden Cardiac Death, and Ventricular Arrhythmias. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 480-488.	1.4	45
13	Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease. <i>Kidney International Reports</i> , 2017, 2, 1122-1131.	0.8	39
14	Improving Ascertainment of Sudden Cardiac Death in Patients with End Stage Renal Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 116-122.	4.5	25
15	Sudden Cardiac Death in Hemodialysis Patients: A Comprehensive Care Approach to Reduce Risk. <i>Blood Purification</i> , 2012, 33, 183-189.	1.8	25
16	Outcomes for Hemodialysis Patients Given Cardiopulmonary Resuscitation for Cardiac Arrest at Outpatient Dialysis Clinics. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 461-470.	6.1	20
17	Cinacalcet, dialysate calcium concentration, and cardiovascular events in the <scp>EVOLVE</scp> trial. <i>Hemodialysis International</i> , 2016, 20, 421-431.	0.9	19
18	Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy. <i>Kidney International</i> , 2010, 77, 753-755.	5.2	14

#	ARTICLE	IF	CITATIONS
19	Coronary artery disease in chronic kidney disease: highlights from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 642-644.	5.2	11
20	Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis. <i>JAMA Cardiology</i> , 2022, 7, 75.	6.1	11
21	Trends in Use and In-Hospital Outcomes of Subcutaneous Implantable Cardioverter Defibrillators in Patients Undergoing Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1622-1630.	4.5	10
22	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , 2017, 119, 886-892.	1.6	9
23	Dialysate potassium concentration: Should mass balance trump electrophysiology?. <i>Seminars in Dialysis</i> , 2018, 31, 569-575.	1.3	9
24	Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-stage Kidney Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e015969.	3.7	9
25	In-Hospital Cardiac Arrest Resuscitation Practices and Outcomes in Maintenance Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 219-227.	4.5	9
26	Racial Differences in AKI Incidence Following Percutaneous Coronary Intervention. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 654-662.	6.1	9
27	Apolipoprotein L1 Genetic Variants Are Associated with Chronic Kidney Disease but Not with Cardiovascular Disease in a Population Referred for Cardiac Catheterization. <i>CardioRenal Medicine</i> , 2017, 7, 96-103.	1.9	8
28	Association between patient race and staff resuscitation efforts after cardiac arrest in outpatient dialysis clinics: A study from the CARES surveillance group. <i>Resuscitation</i> , 2020, 156, 42-50.	3.0	8
29	Azithromycin use increases the risk of sudden cardiac death in patients with hemodialysis-dependent kidney failure. <i>Kidney International</i> , 2022, 102, 894-903.	5.2	6
30	A Pilot Study Using an Implantable Device to Characterize Cardiac Arrhythmias in Hemodialysis Patients: Implications for Future Research. , 2012, 17, 159-159.		5
31	Impact of Kidney Function on Effects of the Dietary Approaches to Stop Hypertension (Dash) Diet. <i>Journal of Hypertension: Open Access</i> , 2013, 03, .	0.2	5
32	Sudden cardiac arrest in ESRD patients. <i>Clinical Nephrology</i> , 2014, 81, 121-131.	0.7	5
33	Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 670-679.	1.9	5
34	Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2021, 27, 1175-1184.	1.7	3
35	The Association of Kidney Function and Albuminuria With the Risk and Outcomes of Syncope: A Population-Based Cohort Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1631-1640.	1.7	2
36	Barriers and Facilitators to Performing Cardiopulmonary Resuscitation During Treatment in Outpatient Hemodialysis Clinics: A Qualitative Study. <i>Nephrology Nursing Journal</i> , 2020, 47, 401.	0.2	2

#	ARTICLE	IF	CITATIONS
37	Facility-Level Factors and Racial Disparities in Cardiopulmonary Resuscitation within US Dialysis Clinics. <i>Kidney360</i> , 2022, 3, 1021-1030.	2.1	2
38	Implantable Defibrillators for Primary Prevention of Sudden Death in Patients on Dialysis. <i>American Journal of Kidney Diseases</i> , 2019, 74, 857-860.	1.9	1
39	Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1669-1671.	3.2	1
40	Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: CON. <i>Kidney360</i> , 2021, 2, 13-15.	2.1	1
41	Racial Disparities in Invasive Management for Patients With Acute Myocardial Infarction With Chronic Kidney Disease. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011171.	3.9	1
42	Barriers and Facilitators to Performing Cardiopulmonary Resuscitation During Treatment in Outpatient Hemodialysis Clinics: A Qualitative Study. <i>Nephrology Nursing Journal</i> , 2020, 47, 401-411.	0.2	1
43	Do Implantable Cardioverter-Defibrillators Lower the Risk of Sudden Death and Total Mortality in Patients with End-Stage Renal Disease?. <i>Current Cardiovascular Risk Reports</i> , 2017, 11, 1.	2.0	0
44	Utility of implantable cardioverter defibrillators in chronic kidney disease. <i>Kidney International</i> , 2018, 93, 1028-1030.	5.2	0
45	Increased eGFR Variability is Observed in Patients with HFrEF Compared to no HF or HFpEF in the Setting of Chronic Kidney Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, S92.	1.7	0
46	Authorsâ€™ Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1137-1138.	6.1	0
47	In-Hospital Cardiopulmonary Resuscitation in Patients Receiving Maintenance Dialysis: Glass Half Full or Half Empty?. <i>Kidney Medicine</i> , 2022, 4, 100399.	2.0	0